How the doctor can counter commercial bias in the dissemination of pharmacotherapeutic knowledge

Journal of Nervous and Mental Disease

Volumn 190, Issue 9, 2002, Pages 593-596

  Carpenter Jr , William T ^a  

^a MARYLAND PSYCHIATRIC RESEARCH CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HALOPERIDOL; PSYCHOTROPIC AGENT; NEUROLEPTIC AGENT;

CLINICAL PRACTICE; DOCTOR PATIENT RELATION; DRUG EFFECT; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG INDUSTRY; DRUG MARKETING; DRUG RESPONSE; DYSPHORIA; ETHICS; HUMAN; LONG QT SYNDROME; MARKET; MEDICAL INFORMATION; MEDICAL PRACTICE; MEDICAL RESEARCH; NOTE; PSYCHOPHARMACOLOGY; SEXUAL DYSFUNCTION; ARTICLE; CLINICAL TRIAL; DRUG INFORMATION; DRUG THERAPY; FINANCIAL MANAGEMENT; MASS COMMUNICATION; MENTAL DISEASE; METHODOLOGY; PUBLISHING; SCHIZOPHRENIA; STANDARD; STATISTICS;

ANTIPSYCHOTIC AGENTS; CLINICAL TRIALS; DIFFUSION OF INNOVATION; DRUG INDUSTRY; DRUG INFORMATION SERVICES; DRUG THERAPY; HUMANS; MENTAL DISORDERS; PHYSICIAN'S PRACTICE PATTERNS; PUBLICATION BIAS; RESEARCH DESIGN; RESEARCH SUPPORT; SCHIZOPHRENIA;

EID: 0036731551     PISSN: 00223018     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005053-200209000-00003     Document Type: Note

References (21)

1. Agnew B (2000) HHS conference on conflict of interest in clinical research will raise a new question: should research universities worry about their own conflicts of interest? Washington Fax July 20:2000. Available from: http://www.washington-fax. com.
2. Am Psychiatric Association (1997) Practice guideline for the treatment of patients with schizophrenia. Am J Psychiatry 154:1-63.
3. Angell M (2000) Is academic medicine for sale? The New England J of Medicine 342:1516-1518.
4. Bodenheimer T (2000) Uneasy alliance: clinical investigators and the pharmaceutical industry. The New England J of Medicine 342:1539-1544.
5. Carpenter WT, Conley RR (2001) Industry phase IV trials are of little or no value (PRO/CON). The J of Psychotic Disorders: Reviews & Commentaries 4:3,13,16.
6. Carpenter WT (2002) From clinical trial to prescription. Archives of General Psychiatry, News and Views 59:282-285.
7. Cohen R (2000, September 24) Conference call. New York Times. Magazine section: pp. 30-32.
8. Davis JM and Chen N (2001) The effects of olanzapine on the 5 dimensions of schizophrenia derived by factor analysis: combined results of the N Am and international trials. J of Clinical Psychiatry 62:757-771.
9. Davis JM, Chen N (2002) Clinical profile of an atypical antipsychotic: Risperidone. Schizophrenia Bulletin 28:43-61.
10. DeAngelis CD (2000) Conflict of interest and the public trust. JAMA 284:2237-2238.
11. Geddes JR, Freemantle N, Harrison P, Bebbington PE (2000) Atypical antipsychotics in the treatment of schizophrenia systematic overview and meta-regression analysis. British Medical J 321:1371-1376.
12. Kane JM (1996) Drug Therapy. Schizophrenia The New England J of Medicine 334:34-41.
13. Klein DF, Thase ME, Endicott J, Adler L, Glick I, Kalali A, Leventer S, Mattes J, Ross P, Bystritsky A (2002) Improving clinical trials: Am Society of Clinical Psychopharmacology recommendations. Archives of General Psychiatry 59:272-278.
14. Korn S (2000) Conflicts of interest in biomedical research. JAMA 284:2234-2237.
15. Lehman AF, Carpenter WT, Goldman HH, Steinwachs DM (1995) Treatment outcomes in schizophrenia: implications for practice, policy, and research. Schizophr Bull 21:669-677.
16. Marder SR, Essock SM, Miller AL, Buchanan RW, Davis JM, Kane JM, Lieberman J, Schooler NR (2002) The Mount Sinai Conference on the pharmacotherapy of schizophrenia. Schizophrenia Bulletin 28:5-16.
17. Miller AL, Chiles JA, Chiles JK, Crismon MD, Shon SP, Rush AJ (1999) The TMAP Schizophrenia Algorithms. J of Clinical Psychiatry 60:649-657.
18. Peterson M (2000, August 27) What's black and white and sell medicine? New York Times. section 3: p. 1.
19. Press E, Washburn J (2000, March) The kept university. The Atlantic Monthly.
20. Rush AJ, Rago WV, Crismon ML, Toprac MG, Shon SP, Suppes T, Miller AL, Trivedi MH, Swann AC, Biggs MM, Shores-Wilson K, Kashner TM, Pigott T, Chiles JA, Gilbert DA, Altshuler KA (1999) Medication treatment of the severely and persistently mentally ill: The Texas Medication Algorithm Project. J of Clinical Psychiatry 60:284-291.
21. Safer DJ (2002) Design and Reporting Modifications. J Nerv Ment Dis 190:583-592.